Circassia Pharmaceuticals Plc (CIR):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Circassia Pharmaceuticals Plc (CIR) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7065
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Circassia Pharmaceuticals plc (Circassia) develops and manufactures drugs for the treatment of allergy and respiratory diseases such as asthma. The company’s marketed products include Niox used to assist asthma management and Tudorza for the treatment of chronic obstructive pulmonary disease. The company had several inhaled medicines in pipeline intended for the treatment chronic obstructive pulmonary disease (COPD), which include single and combination dose products. The company offers its products to COPD and asthma specialists in the US, the UK, Germany and other countries through its network of partners. Circassia is headquartered in Oxford, England, the UK.

Circassia Pharmaceuticals Plc (CIR) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Circassia Pharmaceuticals Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Circassia Pharmaceuticals Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Circassia Pharmaceuticals Plc, Medical Equipment, Deal Details 10
Venture Financing 10
Prosonix Raises Additional US$9 Million In Series B Financing Round 10
Partnerships 12
Circassia Pharma Enters into Licensing Agreement with NanoPass Technologies 12
Aerocrine Enters Into Licensing Agreement With Medisoft 13
Aerocrine Enters Into Distribution Agreement With Shanghai Pharma For Niox Mino And Test Kits 14
Aerocrine Enters Into Distribution Agreement With Stallergenes For Niox Mino 15
Centre of Excellence for Prevention of Organ Failure Enters Into Co-Development Agreement With Adiga Life Sciences For Proteomic And Genomic Biomarkers 16
Equity Offering 17
Aerocrine Raises USD60 Million in Rights Offering of Shares 17
Aerocrine Completes Private Placement Of Shares For US$15 Million 19
Aerocrine Completes Rights Offering Of Common Stock For US$36 Million 20
Acquisition 21
AstraZeneca to Acquire Additional 5.7% Stake in Circassia Pharma 21
Circassia Pharmaceuticals Acquires Aerocrine 22
Circassia Pharma Acquires Prosonix for USD157.6 Million 24
Circassia Pharmaceuticals Plc – Key Competitors 26
Circassia Pharmaceuticals Plc – Key Employees 27
Circassia Pharmaceuticals Plc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Sep 27, 2018: Circassia – Interim results for the six months ended 30 June 2018 29
Sep 27, 2018: Circassia Pharmaceuticals interim results for the six months ended 30 june 2018 33
Apr 24, 2018: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2017 47
Sep 27, 2017: Circassia Pharmaceuticals: Interim Results for the Six Months Ended 30 June 2017 48
Apr 25, 2017: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2016 49
Corporate Communications 50
Feb 13, 2018: Circassia Announces Changes to its Board of Directors 50
Apr 25, 2017: Circassia Announces Non-Executive Director Retirements 51
Government and Public Interest 52
Nov 29, 2017: Circassia Welcomes New NICE Guidelines Recommending Use of FeNO Testing in Asthma Diagnosis 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Circassia Pharmaceuticals Plc, Medical Equipment, Key Facts, 2017 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Circassia Pharmaceuticals Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Circassia Pharmaceuticals Plc, Deals By Market, 2012 to YTD 2018 8
Circassia Pharmaceuticals Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Prosonix Raises Additional US$9 Million In Series B Financing Round 10
Circassia Pharma Enters into Licensing Agreement with NanoPass Technologies 12
Aerocrine Enters Into Licensing Agreement With Medisoft 13
Aerocrine Enters Into Distribution Agreement With Shanghai Pharma For Niox Mino And Test Kits 14
Aerocrine Enters Into Distribution Agreement With Stallergenes For Niox Mino 15
Centre of Excellence for Prevention of Organ Failure Enters Into Co-Development Agreement With Adiga Life Sciences For Proteomic And Genomic Biomarkers 16
Aerocrine Raises USD60 Million in Rights Offering of Shares 17
Aerocrine Completes Private Placement Of Shares For US$15 Million 19
Aerocrine Completes Rights Offering Of Common Stock For US$36 Million 20
AstraZeneca to Acquire Additional 5.7% Stake in Circassia Pharma 21
Circassia Pharmaceuticals Acquires Aerocrine 22
Circassia Pharma Acquires Prosonix for USD157.6 Million 24
Circassia Pharmaceuticals Plc, Key Competitors 26
Circassia Pharmaceuticals Plc, Key Employees 27
Circassia Pharmaceuticals Plc, Subsidiaries 28

List of Figures
Circassia Pharmaceuticals Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Circassia Pharmaceuticals Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Circassia Pharmaceuticals Plc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Circassia Pharmaceuticals Plc (CIR):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ampio Pharmaceuticals Inc (AMPE):企業の財務・戦略的SWOT分析
    Summary Ampio Pharmaceuticals Inc (Ampio), formerly Chay Enterprises Inc is a biopharmaceutical company that discovers and develops novel therapeutic candidates for inflammatory conditions. The company develops compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by …
  • United Orthopedic Corp (4129)-医療機器分野:企業M&A・提携分析
    Summary United Orthopedic Corp (UOC) is a medical device company that designs, manufactures and distributes orthopedic implants and instrument sets. The company’s product categories include knee replacement systems, hip replacement systems, and oncology products. Its hip replacement systems include …
  • ICF International, Inc.:企業の戦略・SWOT・財務情報
    ICF International, Inc. - Strategy, SWOT and Corporate Finance Report Summary ICF International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Gale Pacific Ltd (GAP):企業の財務・戦略的SWOT分析
    Gale Pacific Ltd (GAP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Proteus Digital Health Inc:企業の戦略的SWOT分析
    Proteus Digital Health Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Dairy Crest Group plc:企業の戦略・SWOT・財務情報
    Dairy Crest Group plc - Strategy, SWOT and Corporate Finance Report Summary Dairy Crest Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Data Respons ASA (DAT):企業の財務・戦略的SWOT分析
    Summary Data Respons ASA (Data Respons) is an information technology company that offers software products and embedded solutions. The company's products include storage and memory, handheld tablets, embedded boards, panel PCs and displays, systems and platforms, and industrial communication product …
  • Oltchim SA (OLT):企業の財務・戦略的SWOT分析
    Summary Oltchim SA (Oltchim) is a chemical company that manufactures and markets petrochemical products. The company offers inorganic, macro molecular and organic synthesis products. Its inorganic products include caustic soda, liquid chlorine, hydrochloric acid and sodium hypochlorite. Oltchim's ma …
  • Ribomic Inc (4591):製薬・医療:M&Aディール及び事業提携情報
    Summary Ribomic Inc (Ribomic), a subsidiary of Otsuka Pharmaceutical Co Ltd, is a biopharmaceutical venture company. The company develops molecular targeted pharmaceutical drugs using RNA aptamers. Its technology includes RiboART system a platform technology to treat therapeutic aptamers. Ribomic’s …
  • Original BioMedicals Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Original BioMedicals Co Ltd (OBM) is a biotechnology company that develops new drug delivering systems to deal with unmet clinical needs in the therapeutic areas of oncology, hematology and immunology. The company’s pipeline products include A01, A02 and P01. Its pipeline product OBM-A01 is …
  • Immusoft Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Immusoft Corp (Immusoft) is a biotechnology start-up company that focuses on the development of autologous cell therapy platform for the treatment of genetic diseases. The company’s technology includes immune system programming (ISP) technology, gene delivery technology and lymphopoiesis cul …
  • Sanofi Genzyme:企業の戦略・SWOT・財務分析
    Sanofi Genzyme - Strategy, SWOT and Corporate Finance Report Summary Sanofi Genzyme - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • U.S. Geothermal Inc. (HTM):企業の財務・戦略的SWOT分析
    U.S. Geothermal Inc. (HTM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Briggs & Stratton Corporation:企業の戦略・SWOT・財務分析
    Briggs & Stratton Corporation - Strategy, SWOT and Corporate Finance Report Summary Briggs & Stratton Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • California Pizza Kitchen, Inc.:企業の戦略・SWOT・財務分析
    California Pizza Kitchen, Inc. - Strategy, SWOT and Corporate Finance Report Summary California Pizza Kitchen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Kosmos Energy Ltd (KOS):企業の財務・戦略的SWOT分析
    Kosmos Energy Ltd (KOS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Montisera Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Montisera Ltd (Montisera) focuses on discovering, developing and commercialising bioactive compounds and molecules for pharmaceutical and food industries. Its pipeline portfolio includes Montisera D15 1 for alcoholism; Montisera D 4 for treating lower urinary tract symptoms, Montisera D15 2 …
  • Koninklijke Ahold Delhaize N.V.:戦略・SWOT・企業財務分析
    Koninklijke Ahold Delhaize N.V. - Strategy, SWOT and Corporate Finance Report Summary Koninklijke Ahold Delhaize N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • PUMA SE:企業の戦略・SWOT・財務情報
    PUMA SE - Strategy, SWOT and Corporate Finance Report Summary PUMA SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Kinden Corporation:企業の戦略・SWOT・財務情報
    Kinden Corporation - Strategy, SWOT and Corporate Finance Report Summary Kinden Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆